Pharmacokinetics and drug interactions of medications used to treat hepatitis C virus infection in the setting of chronic kidney disease and kidney transplantation
Authors:
- 25 April 2018
- journal article
- review article
- Published by Wiley in Hemodialysis International
- Vol. 22 (S1) , S22-S35
Abstract
Hepatitis C infection in patients with chronic kidney disease or kidney transplant carries higher morbidity and mortality compared to noninfected patients. Historically, patients with advanced kidney disease and kidney transplant recipients were undertreated given the multiple adverse effects and limited efficacy of interferon‐based therapies for chronic hepatitis C. The development of direct‐acting antivirals in the past few years has opened an unprecedented opportunity for treating these populations. However, the impaired renal clearance of some of these medications in patients with kidney disease, and the potential interactions of antiviral therapies with immunosuppressants after kidney transplantation, present some challenges in choosing the proper regimen. This review provides an overview of the essential pharmacokinetics and drug interactions of relevant antiviral therapies in the treatment of chronic hepatitis C in patients with advanced kidney disease and after kidney transplantation.Keywords
This publication has 48 references indexed in Scilit:
- Is genotype 3 of the hepatitis C virus the new villain?Hepatology, 2014
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 InfectionNew England Journal of Medicine, 2014
- Interferon-Based Anti-Viral Therapy for Hepatitis C Virus Infection after Renal Transplantation: An Updated Meta-AnalysisPLOS ONE, 2014
- HCV Genotype 3 Is Associated With an Increased Risk of Cirrhosis and Hepatocellular Cancer in a National Sample of U.S. Veterans With HCVHepatology, 2014
- Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevirHepatology, 2013
- Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalenceHepatology, 2013
- Hepatitis C Virus Antibody Status and Survival After Renal Transplantation: Meta-Analysis of Observational StudiesAmerican Journal of Transplantation, 2005
- Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPSKidney International, 2004
- Structural biology of hepatitis C virusHepatology, 2004
- Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infectionLiver Transplantation, 2002